Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study
| العنوان: | Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study |
|---|---|
| المؤلفون: | Blandine Tramunt, Emmanuel Disse, Nicolas Chevalier, Lyse Bordier, Laurent Cazals, Olivier Dupuy, Michel Marre, Odette Matar, Laurent Meyer, Chloé Noilhan, Caroline Sanz, Paul Valensi, Fritz-Line Velayoudom, Jean-François Gautier, Pierre Gourdy |
| المصدر: | Diabetes Therapy. 13:1947-1963 |
| بيانات النشر: | Springer Science and Business Media LLC, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Endocrinology, Diabetes and Metabolism, Internal Medicine |
| الوصف: | Combining basal insulin (BI) with glucagon-like peptide-1 receptor agonist (GLP-1RA) is recognized as a relevant option to optimize glucose control in type 2 diabetes (T2D). The EASY real-world study aimed to evaluate the modalities of initiation and the effectiveness of the insulin Degludec plus Liraglutide (IDegLira) fixed-ratio combination in the French health care system.A retrospective analysis included all patients with T2D and prior injectable therapy (GLP1-RA and/or insulin) who started treatment with IDegLira from September 2016 to December 2017 in 11 French diabetes centers. Baseline characteristics, reasons for IDegLira initiation, and modes of implementation were collected from the medical records. Changes in HbAIDegLira was initiated in 629 patients previously treated with GLP-1RA alone (11.6%), insulin alone (31.5% including 16.5% with BI and 14.9% with multiple daily injections [MDI]) or a free combination of GLP-1RA and insulin (56.9% including 44.8% with BI and 12.1% with MDI), associated or not with oral agents. IDegLira starting dose (mean of 29 ± 11 dose steps) most often exceeded the recommended dose, and was significantly correlated with prior BI but not GLP-1RA dosage. At initiation, mean age, body mass index (BMI) and HbAWhile providing new information on the use of IDegLira in the French healthcare system, these data confirm the effectiveness of this fixed-ratio combination in the management of T2D. |
| تدمد: | 1869-6961 1869-6953 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1757f900d0de1b4824bab0b80b47accc https://doi.org/10.1007/s13300-022-01327-8 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....1757f900d0de1b4824bab0b80b47accc |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 18696961 18696953 |
|---|